TC BioPharm Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Income tax credit (Tables)

12 Months Ended

Dec. 31, 2021

	Year ended December 31,			Year ended December 31,			Year ended December 31,
	2021			2020			2019
	£			£			£
Current tax
Corporation tax credit		1,407,542			1,171,928			826,065
Total current tax credit		1,407,542			1,171,928			826,065

Reconciliation of loss before tax to the tax credit for the year
Loss before tax		14,983,467			6,629,844			6,894,049

Loss on ordinary activities multiplied by the standard rate of tax of 19% (2020: 19% and 2019: 19%)		2,846,859			1,259,670			1,309,869

Non-deductible expenses		(1,641,974	)		(4,556	)		(3,821	)
Deferred tax movement on unrecognized fixed asset differences		(103,418	)		(157,728	)		56,935
Deferred tax movement on unrecognized timing differences		42,462			2,660			2,616
Deferred tax movement on share-based payments		-			(152,895	)		(158,800	)
Deferred tax asset not recognized		(342,227	)		(278,753	)		(695,881	)
Additional allowance in respect of enhanced R&D relief		1,042,213			868,918			667,671
Surrender of tax losses for R&D tax credit refund		(1,843,915	)		(1,537,316	)		(1,178,589	)
R&D tax credits generated		1,407,542			1,171,928			826,065
Current tax credit		1,407,542			1,171,928			826,065